Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine

被引：80

作者：

Shinko, Diana ^{[1
]}

Diakos, Connie I. ^{[2
,3
,4
]}

Clarke, Stephen J. ^{[2
,3
,4
]}

Charles, Kellie A. ^{[1
]}

机构：

[1] Univ Sydney, Sydney Med Sch, Discipline Pharmacol, Sydney, NSW, Australia

[2] Royal North Shore Hosp, Northern Sydney Canc Ctr, St Leonards, NSW, Australia

[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia

[4] Kolling Inst Med Res, Bill Walsh Translat Res Labs, St Leonards, NSW, Australia

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 04期

关键词：

FECAL MICROBIOTA TRANSPLANTATION; RANDOMIZED CONTROLLED-TRIAL; ULCERATIVE-COLITIS;

D O I：

10.1002/cpt.789

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Over the last decade there has been significant progress towards the development of personalized or "precision" medicine for many patients with cancer. However, there still remain subpopulations of cancer patients that do not possess a tumor mutation profile that is successfully targeted by the newer molecular anticancer drugs and further personalized approaches are needed. The presence of cancer-related systemic inflammation represents an underappreciated subpopulation of cancer patients needing personalized therapy. For similar to 25% of all advanced cancer patients, regardless of histological subtype, the patients with systemic inflammation have significantly poorer response to chemotherapy and also shorter overall survival compared to those cancer patients without inflammation. The development of cancer-related systemic inflammation involves interactions between host and tumor cells that are potential new drug targets in cancer chemotherapy. In this review we discuss the challenges and clinical opportunities to develop new therapeutic strategies for this underappreciated drug target.

引用

页码：599 / 610

页数：12

共 5 条

[1] Fecal microbiota transplantation as therapy for inflammatory bowel disease: A systematic review and meta-analysis (Publication with Expression of Concern) [J].

Colman, Ruben J. ;

Rubin, David T. .

JOURNAL OF CROHNS & COLITIS, 2014, 8 (12) :1569-1581

[2] Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial [J].

Moayyedi, Paul ;

Surette, Michael G. ;

Kim, Peter T. ;

Libertucci, Josie ;

Wolfe, Melanie ;

Onischi, Catherine ;

Armstrong, David ;

Marshall, John K. ;

Kassam, Zain ;

Reinisch, Walter ;

Lee, Christine H. .

GASTROENTEROLOGY, 2015, 149 (01) :102-+

[3] Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial [J].

Paramsothy, Sudarshan ;

Kamm, Michael A. ;

Kaakoush, Nadeem O. ;

Walsh, Alissa J. ;

van den Bogaerde, Johan ;

Samuel, Douglas ;

Leong, Rupert W. L. ;

Connor, Susan ;

Ng, Watson ;

Paramsothy, Ramesh ;

Xuan, Wei ;

Lin, Enmoore ;

Mitchell, Hazel M. ;

Borody, Thomas J. .

LANCET, 2017, 389 (10075) :1218-1228

[4] Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis [J].

Rossen, Noortje G. ;

Fuentes, Susana ;

van der Spek, Mirjam J. ;

Tijssen, Jan G. ;

Hartman, Jorn H. A. ;

Duflou, Ann ;

Lowenberg, Mark ;

van den Brink, Gijs R. ;

Mathus-Vliegen, Elisabeth M. H. ;

de Vos, Willem M. ;

Zoetendal, Erwin G. ;

D'Haens, Geert R. ;

Ponsioen, Cyriel Y. .

GASTROENTEROLOGY, 2015, 149 (01) :110-+

[5]

van Nood E, 2013, NEW ENGL J MED, V368, P2145, DOI [10.1056/NEJMoa1205037, 10.1056/NEJMc1303919]

← 1 →